Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MNT

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    59 result(s) found for: MNT. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2023-001084-54 Sponsor Protocol Number: DEN-306 Start Date*: 2025-06-13
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Randomized, Age-Descending, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Safety and Immunogenicity of 2 Doses of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (T...
    Medical condition: Dengue Fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10012310 Dengue fever PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-004015-49 Sponsor Protocol Number: FLU010 Start Date*: 2019-03-14
    Sponsor Name:Vaccitech Ltd
    Full Title: Efficacy of MVA-NP+M1 in the influenza H3N2 Human Challenge model
    Medical condition: influenza disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006057-28 Sponsor Protocol Number: CAIN457A2308 Start Date*: 2012-06-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after twelve weeks of treatment, and to assess the safety...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003463-97 Sponsor Protocol Number: RVL-VRL01 Start Date*: 2021-09-24
    Sponsor Name:Revelation Biosciences, Inc.
    Full Title: A Phase IIb Study Assessing Prophylactic Efficacy of Intranasal REVTx-99 in an H3N2 Influenza Challenge Model in Healthy Subjects.
    Medical condition: Influenza A
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2024-000341-27 Sponsor Protocol Number: DEN-324 Start Date*: 2024-12-13
    Sponsor Name:Takeda
    Full Title: A Randomized, Double-Blind, Placebo-Controlled (Participants aged 18 to 60 years) and Open-Label (Participants aged 4 to 17 years), Phase 2/3 Trial to Evaluate the Immunogenicity and Safety of 2 do...
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2012-002609-22 Sponsor Protocol Number: CAIN457A2309 Start Date*: 2012-10-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tol...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003979-34 Sponsor Protocol Number: DEN-301 Start Date*: 2018-12-13
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy C...
    Medical condition: The main purpose of this study is to evaluate the efficacy of 2 doses of Tetravalent Dengue Vaccine Candidate (TDV) in preventing symptomatic dengue fever of any severity and due to any of the four...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023512-13 Sponsor Protocol Number: CAIN457A2302 Start Date*: 2011-05-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability and lo...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) IS (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003414-17 Sponsor Protocol Number: CACZ885H2357E3 Start Date*: 2011-11-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label extension study of CACZ885H2356E2 and CACZ885H2357E2 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindica...
    Medical condition: Treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) EE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002790-22 Sponsor Protocol Number: EFC13752 Start Date*: 2014-06-02
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An open-label, randomized, parallel group study assessing the immunogenicity and safety of sarilumab administered as monotherapy in patients with active rheumatoid arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003927-12 Sponsor Protocol Number: DRI15928 Start Date*: 2019-03-06
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) NL (Completed) SK (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002500-91 Sponsor Protocol Number: RPC01-3001 Start Date*: 2015-10-12
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) ES (Completed) BG (Completed) SK (Completed) GR (Completed) PL (Completed) LV (Completed) EE (Completed) LT (Completed) PT (Completed) SE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000648-25 Sponsor Protocol Number: 165-502 Start Date*: 2019-06-28
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 3b, Open-Label, Single Arm, Multi-Centre Study to Assess the Safety and Efficacy of Pegvaliase (BMN 165) Treatment in adults With Phenylketonuria Not Controlled With Current Management
    Medical condition: Phenylketonuria (PKU)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10034873 Phenylketonuria (PKU) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Not Authorised) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001028-80 Sponsor Protocol Number: ACT14604 Start Date*: 2016-11-08
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Efficacy and safety of SAR156597 in the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc): A randomized, double-blind, placebo-controlled, 24-week, proof of concept study
    Medical condition: Systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000171021 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) BE (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004783-30 Sponsor Protocol Number: ARD12858-MOZ23510 Start Date*: 2013-01-21
    Sponsor Name:Sanofi aventis recherche et développement
    Full Title: A pilot, exploratory, randomized, phase 2 safety study evaluating tumor cell (plasma cell) mobilization and apheresis product contamination in plerixafor plus non-pegylated G-CSF mobilized patients...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) LT (Completed) SE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002664-10 Sponsor Protocol Number: CNVA237B2301 Start Date*: 2014-03-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) BE (Completed) FI (Prematurely Ended) EE (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002057-38 Sponsor Protocol Number: CQVA149A2339 Start Date*: 2012-08-16
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A placebo and active controlled study to assess the long-term safety of once daily QVA149 for 52 weeks in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe airflow limit...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) HU (Completed) GB (Completed) LV (Completed) EE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000960-93 Sponsor Protocol Number: CNVA237A2314 Start Date*: 2012-05-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week treatment, randomized, blinded, double-dummy, parallel-group study to assess the efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.) in patients ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Completed) EE (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005100-14 Sponsor Protocol Number: CQMF149E2201 Start Date*: 2012-05-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double-dummy, 4-week treatment, parallel-group study to evaluate the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in a...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) EE (Completed) LT (Completed) NL (Completed) LV (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004850-32 Sponsor Protocol Number: EFC13794 Start Date*: 2016-06-17
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabe...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 26 13:14:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA